Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action antagonists, modulators |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TL1A modulators(Tumor necrosis factor superfamily member 15 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammation | Discovery | United States | 01 Nov 2025 |






